Geldanamycin: Biotin
Hsp90 inhibitor
Product Specifications
Background
Geldanamycin is a benzoquinoid ansamycin produced by Streptomyces hygroscopicus. It binds specifically to heat shock protein HSP90 and downregulates target proteins including tyrosine kinases, steroid receptors, transcription factors and cell cycle regulatory kinases (1,2). It induces the inactivation, destabilization and eventual degradation of HIF-1α (3). It is also an inhibitor of pp60src tyrosine kinase and of c-myc gene expression in murine lymphoblastoma cells. It inhibits the transforming activity of abl, erbB, fps, src, and yes (4). Geldanamycin is capable of destabilizing several oncogene and proto-oncogene products; it is a potent inhibitor of the nuclear hormone receptor family (5). It protects against α-synuclein toxicity to dopaminergic neurons in Drosophila, and destabilizes mutant p53 protein from a number of breast, leukemic, and prostate cell lines (6). Inhibits basal and hypoxia-induced expression of c-Jun (IC50=75nM) and abolishes hypoxia-induced increase in c-Jun N-terminal kinase (JNK) activity. Inhibits telomerase activity through inhibition of HSP90, a chaperone required for the assembly and activation of telomerase in human cells (6). It is ~10-fold more potent than herbimycin A. Looking for more information on HSP90? Visit our new HSP90 Scientific Resource Guide at http://www.HSP90.ca.
CAS Number
30562-34-6
Product Name Alternative
(4E,6Z,8S,9S,10E,12S,13R,14S,16R) -13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1 (21),4,6,10,18-pentaen-9-yl carbamate
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cancer | Heat Shock
Purity
>98%
Weight
0.001
Format
Purple Solid
Solubility
Soluble in DMSO
Molecular Formula
C55H87N7O17S
Molecular Weight
560.6
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Whitesell L., et al. (1994) Proc. Natl. Acad. Sci. USA 91:8324.
2. Neckers L. (2002) Trends Mol. Med. 8: S55.
3. Mabjeesh N.J., et al. (2002) Cancer Res. 62: 2478.
4. Chavany C., et al. 1996) Amer. Society Biochem Mol Bio. 9: 4974-4977.
5. Villa R., et al. (2003) Carcinogenesis. 24(5): 851-9.
6. Yamaki H., Iguchi-Ariga S.M., and Ariga H. (1989) J Antibiot (Tokyo). 42(4): 604-10.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog